Stanford V

Stanford V (usually spoken as Stanford Five) is a chemotherapy regimen (with or without accompanying Radiation therapy) intended as a first line treatment for Hodgkin's lymphoma. The regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens such as ABVD. The chemical agents used are:

Drug Regimen

The chemotherapy part of Stanford V treatment can last anywhere from 8 to 12 weeks, depending on the staging of the disease. In many cases, this is followed by radiation therapy for anywhere from 2 to 6 weeks to the affected areas of the body.

Stanford V is a more rigorously administered form of chemotherapy, with treatments roughly twice as fast as those of other Hodgkin's lymphoma treatments. However, in a randomized controlled study, Stanford V was inferior to ABVD. This study has been criticized for not adhering to the proper Stanford V protocol. Specifically, the radiation therapy component following chemotherapy was not properly administered in the Italian study. A retrospective study from the Memorial Sloan-Kettering Cancer Center displayed results similar to the Stanford Cancer Center's own experience. The study concluded that, "Stanford V with appropriate radiotherapy is a highly effective regimen for locally extensive and advanced HL."

...
Wikipedia